Post on 01-Nov-2014
description
Science and Policy Making in Public Health
The example of Blood Safety
Albert FarrugiaSenior Director Global Access, Plasma Protein
Therapeutics Association
2003-2008
Senior Principal Research Scientist, Australian Department of Health and AgeingUniversity of Canberra, Faculty of Applied Science
May 2009
In this discussion, I will seek to make the following points
• Policy making in government is complex and often erratic and confused• While most governments promulgate cost-effectiveness in health care spending,
blood safety measures have been relatively insulated from this measure• Cost – effectiveness in blood safety engages blood experts – AND NO ONE ELSE• Public opinion supports a high level of willingness to pay for blood safety – real
and perceived – and this is only modestly influenced by scientific knowledge• Therefore, measures to further enhance the safety of blood should continue to be
introduced, while focus of scrutiny should be the evidence base for the therapies themselves
Pillars of Australian health policy inputs
E
B
M
CE
PRECAUTIONISM
Contributors to policy choices
• Values
• Interests
• Resources
•Mediated through institutions
•Determined by politics
Volatile mixture -
? Agreement on process
Policy choices are Made at a range of levels within governments, which are “An amorphous mass of interlocking organisations attempting to provide for
the many public service demands of a modern industrial society” and have to be
Negotiated across agencies, which Are dispersed and diffuseDisagree and overlap Pursue contrary understandings of policy objectivesObstruct unacceptable (to them) choicesContest decisions at various levels within themselvesRemake decisions during implementations
As a result - policy making is “inherently difficult, frustrating and only partially effective”
Decision making in the Australian blood system
Areas involved in blood:•Acute Care Division•Regulatory Policy Division•Population Health Division•Etc
Areas involved in blood:•Blood & Tissues Unit•Drug Safety Branch•Devices Section•Manufacturing Assessment Branch•Etc
Decision making and implementation• Interests
– Seek to shape procedures– Intervene at strategic moments– Challenge the validity of administrative decisions
• Implementation– Delivery cannot be guaranteed– Need to ensure understanding and respect– Complex processes demand discretion– Discretion means policy process seldom concluded– Few processes are entirely authoritive– Fewer decisions are quite final
Furler 2001“Health Policy
Electoral Populism Research-based evidence
Selectively exploits and reinforces community (mis)-conceptions
•Value for money•equity•health outcomes•etc
May entail political risk
Furler 2001
Public Service Priorities1 Get government re-elected2 Deliver micoreconomic reform (while husbanding votes)3 Deliver better population health outcomes (without affecting 1 &
2)
throughawareness of mood in marginal electoratesunderstanding of swinging voters’ core valuesknowledge of market research mechanisms
HIV Risks in Repeat Donors in Europe andU.S. versus Australia
Residual Risk per 106 Repeat DonationsIncidence Rate per 105 Person-Years
(95% CI)
DatesCountry
0.51.01.6 (1.0 - 2.3)1/96 - 12/00US
0.50.71.6 (1.2 - 2.0)1/00 - 12/01
1.12.33.8 (2.8 - 5.0)1/96 - 12/00 Italy
1.01.93.2 (2.2 - 4.5)1/97 - 12/99Spain
0.20.40.7 (0.5 - 1.1) 1/97 – NA
(EPFA)
Central Europe
0.40.71.2 (0.7 - 2.0)1/98 - 12/00France
Serology / NAT Estimate
Serology Estimate
Glynn, Kleinman, Wright, Busch. Transfusion 42:966-72, 2002; Australian Red Cross Blood Services data courtesy of Dr. Clive Seed, 7/03
Australia 1/00 - 6/03 0.54 (6 SC in 2.6 million donations) 0.12 (1/ 6.1 million)
The other side of NATSimmonds et al 2002
Staginnus 2006CE of platelet bacterial testing
Australian Government review of alternatives to homologous blood donation
http://www.nba.gov.au/PDF/homologous.pdf
Pre-operative autologous donation should not be promoted, for the following reasons:
· While pre-operative autologous donation reduces the need for homologous blood, any benefit from avoiding the adverse effects of homologous blood has to be balanced against the risks associated with the use of autologous blood or any blood product;
· The chance of receiving a transfusion is significantly increased in those with autologous blood available, magnifying these risks and increasing the costs; and
· In the absence of formal modelling or a properly conducted clinical trial, it is difficult to determine whether the benefits of autologous donation will definitely outweigh the harms.
Cost of Australian Blood Sector
0
2
4
6
8
10
12
14
16
18
$A
us p
er
cap
ita
1990 1995 2000
0.71% of total health care expenditure
29%
Optimal versus maximal safety• Conference - 9/11/96 - by the Medical Advisory Commission to the Blood Transfusion
Council of the Netherlands Red Cross, addressing the issues of 'maximal' versus 'optimal' safety measures for the blood supply.
• Invited were blood transfusion specialists, clinicians, representatives of patient interest groups, the Ministry and Inspectorate of Health and members of parliament.
• Transfusion experts and clinicians were found to advocate an optimal course, following strategies of evidence-based medicine, cost-benefit analyses and medical technology assessment.
• Patient groups depending on blood products, such as haemophilia patients would rather opt for maximal safety.
• Insurance companies would choose likewise, to exclude any risk if possible. • Health care juridical advisers would advise to choose for optimal safety, but to reserve funds
covering the differences with 'maximal safety' in case of litigation. • Politicians and the general public would sooner choose for maximal rather than optimal
security. • The overall impression persists that however small the statistical risk may be, in the eyes of
many it is unacceptable. “This view is very stubborn.”
van der Poel at al Ned Tijdschr Geneeskd. 1998 Feb 7;142(6):285-8
•Cross section of Australians questioned about the importance of costs in setting priorities in health care.
•Generally, respondents felt unfair to discriminate against patients with high cost illness and that costs should not be a major factor in prioritising.
•Majority maintained this view when confronted with its implications in terms total number of people who could be treated and their own chance of receiving treatment if they fall ill.
•Results suggest that
Concern with allocative efficiency, as usually envisaged by the economists, is not shared by the general public
Cost-effectiveness approach may be an excessively simple value system upon resource allocation decision making.
Willingness to pay for autologous donationMoxey at al Transfusion Medicine, 2005, 15, 19–32
0
10
20
30
40
50
60
70
80
90
100
10 10000
Price $A
% w
illi
ng
to
pa
y
Perceptions and preferences regarding PADLee et al Transfusion 38:757-763, 1989
Study group
Study questions Informed Uninformed p
Concern re allogeneic transfusions – 0 to 10 (10 = extreme worry) 6 7 0.75
% selecting 10 28 27 0.73
Median willingness to pay $1100 $1900 0.095
Prefer EPO over PAD %
Yes 44 41 0.545
No 19 23
Not sure 37 36
Prefer PAD despite elimination of all infectious agents from allogeneic blood 56 66 0.202
Yes 56 66 0.202
No 20 17
Not sure 24 18
Prefer PAD even if not recommended by a physician
Yes, definitely 47 44 0.323
Yes, probably 29 30
Not sure 11 10
Probably not 13 12
Definitely not 1 4
24
Evidence-based decision making versus (precautionary) risk management approach
Definitive clinical or epidemio-logical evidence of benefit before application of the measure
Attempt to balance risk prevented by implementation of the measure, versus risk remaining without its introduction, based on incomplete information
The “threat” of pharmaco-economics“What we are seeing, in both Factor VIII and Factor IX is in fact the market has grown rather than
necessarily plasma-derived being used less. So when we were the sole fractionator before recombinant there was a lot of rationing of haemophilic patients, probably as low as - we only probably had about 1.6 IUs per head of population. We now have a target in Australia of 3 international units per hit of population, of which I think plasma will represent 1.8 to 2 and recombinant 1……. But, in essence, I know Canada has gone to a different solution in that scenario. I think it is an expensive solution. I'm not sure clinically it is superior, but it is what it is. I think that in Australia, because we believe in pharmaco-economics, the recombinant products for patients who are well stabilized on plasma-derived there is no evidence that it is a useful thing to do…. because in very few other areas of medicine have we seen such an expensive - such a lot of money spent for such little clinical gain.”
Dr Brian McNamee
Open Forum
Plasma Self-sufficiency in Canada - is it a matter of safety?
National Blood Safety CouncilMarch 29-30, 2001
Blood infections in US hemophiliac birth cohortsCDC survey
HBV (▪), HCV ( ), and HIV-1 ( )▴ ◯ The proportion was zero for HIV after 1984, for HCV after 1992, and for HBV after 1993.
Efficacy of recombinant vs plasma concentrates
Blood 109, 546-551. 2007
28
Variant CJD•BSE emerged as major epidemic in United Kingdom in 1980s and 1990s
– related to feed material used – >180,000 cattle infected– hundreds of cases of BSE in Europe
•exported British cattle •native born bovines fed materials derived from UK
•Magnitude of human epidemic unknown
– early prediction of many thousands of deaths– latest scientific data suggest no more than few hundred
deaths– incubation period very long
•BSE emerged as major epidemic in United Kingdom in 1980s and 1990s
– related to feed material used – >180,000 cattle infected– hundreds of cases of BSE in Europe
•exported British cattle •native born bovines fed materials derived from UK
•Magnitude of human epidemic unknown
– early prediction of many thousands of deaths– latest scientific data suggest no more than few hundred
deaths– incubation period very long
•Transfusion and vCJD
• state of knowledge - 2003
–evidence of transfusion transmissibility elusive
• theoretical considerations suggest possible risk
• scientific data show some cross species transmissibility by blood in
animal experiments
• applicability of animal data remains controversial
• epidemiology has not supported the risk
• state of knowledge - 2009
–evidence of at least 3 transfusion derived vCJD from fresh
components
–most recently putative transmission to hemophiliac
•Transfusion and vCJD
• state of knowledge - 2003
–evidence of transfusion transmissibility elusive
• theoretical considerations suggest possible risk
• scientific data show some cross species transmissibility by blood in
animal experiments
• applicability of animal data remains controversial
• epidemiology has not supported the risk
• state of knowledge - 2009
–evidence of at least 3 transfusion derived vCJD from fresh
components
–most recently putative transmission to hemophiliac
0
5
10
15
20
25
30
Donor deferral policies:
• entirely precautionary (and highly controversial) when implemented
• are they now justified in light of new knowledge?
Donor deferral policies:
• entirely precautionary (and highly controversial) when implemented
• are they now justified in light of new knowledge?
http://www.nba.gov.au/pdf/factor_VIII_IX.pdf
Special Expert Committee on TransmissibleSpongiform Encephalopathies
June 2002
" Although the theoretical risks from plasma-derived AHF are very small, they cannot be saidto totally negligible. It is prudent to recommendthat, as soon as feasible, AHF be made availablein recombinant form, or as a product of apurification process that is proven to reduce prioncontent by at least 7 logs."
“……..The Government has agreed to fund access to recombinant clottingfactors for haemophilia patients. A small number will not be able to userecombinant products and will continue to be provided with plasma-derivedclotting factors. The Government will provide ongoing funding of $80.7million over four years, to be supplemented by the States andTerritories……”
P 57
Reality check• Power is diffuse - no single “decision-making process”• Implementation generates options - and new policy• Process must bend to meet circumstances• Problems vary so policy formulation adjusts over time and
place• Political processes are by nature ad hoc, pragmatic and
confused• Long term financial strategies may need to cede to
immediate political priorities• ELECTORAL CONCERNS CAN OVVERRIDE THE MOST
CAREFUL POLICY PROCESS